St. Jude Medical (NYSE:STJ) (St. Paul, Minnesota) has been given the green light by the FDA to resume its IDE trial evaluating the Portico Transcather Aortic Valve Implantation (TAVI) System. The trial, which started in May of last year, was put on hold the following September, due to concerns about reduced leaflet mobility in patients implanted with Portico.

Strand Life Sciences is hoping for a bigger seat at the table in the U.S. next-generation sequencing (NGS) market with the launch of an expanded version of its Stranddvantage pan-cancer genomic profiling test.

Privately held Pulmonx (Denver) said data from two recent studies provide evidence that could lead to doubling the amount of emphysema patients treated with its Zephyr Endobronchial Valve (EBV). The company presented at the American Thoracic Society (ATS; New York) Annual Meeting six-month results of the STELVIO trial and the VENT study, which demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease who received treatment with Zephyr.